Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
Open Access
- 18 May 2006
- Vol. 106 (11), 2437-2444
- https://doi.org/10.1002/cncr.21854
Abstract
BACKGROUND T‐regulatory (TR) cells expressing cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) maintain peripheral immune tolerance and negatively affect host immune responses against cancer. The immunobiologic effects of ticilimumab, a human monoclonal antibody against CTLA‐4, was administered to patients with metastatic melanoma who participated in a Phase I/II clinical trial. METHODS Thirty patients who received ticilimumab at a dose of 10 mg/kg monthly (n = 20) or 15 mg/kg every 3 months (n = 10) were studied at study entry and at 14‐day intervals thereafter to assess lymphocyte immunophenotypes, interleukin (IL)‐2 and IL‐10 production, and the expression of TR‐related genes in peripheral blood mononuclear cells (PBMC) from a subset of patients was studied by real‐time polymerase chain reaction. RESULTS Four of 12 patients with immune‐related adverse events (IRAE) attained objective antitumor responses (ATR), whereas only 1 of 18 patients without IRAE attained ATR (χ2 = 4.0; P = .0455). Patients with ATR had significant reductions in TR cells and constitutive IL‐10 production accompanied by a significant increase in IL‐2 production by activated T cells. Although IRAE+/ATR+ patients demonstrated a positive correlation between CTLA‐4 and glucocorticoid‐induced tumor necrosis factor receptor (GITR) transcripts (Spearman rho = .522; P = .015), IRAE−/ATR− patients had a positive correlation between the transcripts of CTLA‐4 and program death‐1 (PD‐1) receptor (Spearman rho = .891; P = .000). CONCLUSIONS Antitumor responses in patients with metastatic melanoma who were treated with ticilimumab were found to be correlated with reductions in TR cells and constitutive secretion of IL‐10, an increase in IL‐2 production, and a positive correlation between transcripts of CTLA‐4 and GITR. Conversely, a lack of ATR was found to be correlated with steady levels of TR cells and constitutive IL‐10 secretion, and a positive correlation between the transcripts of CTLA‐4 and PD‐1. Cancer 2006. © 2006 American Cancer Society.Keywords
Funding Information
- Career Development award (NCI-P50 CA093459)
- Pfizer Research Global and Development, Groton, CT
This publication has 40 references indexed in Scilit:
- The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cellsImmunological Reviews, 2006
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- Regulation of murine chronic colitis by CD4+CD25- programmed death-1+ T cellsEuropean Journal of Immunology, 2005
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- PD-1 ligands, negative regulators for activation of naïve, memory, and recently activated human CD4+ T cellsCellular Immunology, 2004
- Regulatory T Cells Selectively Express Toll-like Receptors and Are Activated by LipopolysaccharideThe Journal of Experimental Medicine, 2003
- Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-toleranceNature Immunology, 2002
- Type 1 T regulatory cellsImmunological Reviews, 2001
- CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.The Journal of Experimental Medicine, 1996